Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress


LOS ANGELES, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the Crohn’s & Colitis Congress (CCC) Annual Meeting. Drs. Peter M. Clark, of the University of California Los Angeles, and Kenneth A. Schultz, of Trethera, will present preclinical research highlighting the use of Trethera’s deoxycytidine kinase (dCK) inhibitor, TRE-515, that suggests a functional role for nucleoside salvage and dCK in inflammatory bowel disease (IBD) mouse models.

Continue reading here:
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress

Related Posts